Oramed Pharmaceuticals Inc.
ORMP
$2.74
-$0.01-0.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.00M | 2.00M | 2.00M | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00M | 2.00M | 2.00M | -- | 0.00 |
| Cost of Revenue | 1.99M | 1.99M | 1.99M | -- | -- |
| Gross Profit | 13.00K | 13.00K | 13.00K | -- | 0.00 |
| SG&A Expenses | 7.17M | 6.74M | 6.98M | 6.46M | 6.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.01M | 15.67M | 16.32M | 12.78M | 13.06M |
| Operating Income | -13.01M | -13.67M | -14.32M | -12.78M | -13.06M |
| Income Before Tax | 55.74M | -22.22M | -24.51M | -15.92M | 7.16M |
| Income Tax Expenses | 11.94M | 2.01M | 3.77M | 3.18M | 2.77M |
| Earnings from Continuing Operations | 43.81 | -24.22 | -28.28 | -19.10 | 4.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 44.00K | 61.00K | 41.00K | 43.00K | 73.00K |
| Net Income | 43.85M | -24.16M | -28.24M | -19.06M | 4.47M |
| EBIT | -13.01M | -13.67M | -14.32M | -12.78M | -13.06M |
| EBITDA | -12.89M | -13.53M | -14.15M | -12.59M | -12.85M |
| EPS Basic | 1.04 | -0.60 | -0.69 | -0.47 | 0.11 |
| Normalized Basic EPS | -0.13 | -0.14 | -0.15 | -0.13 | -0.14 |
| EPS Diluted | 0.99 | -0.62 | -0.71 | -0.49 | 0.10 |
| Normalized Diluted EPS | -0.13 | -0.14 | -0.15 | -0.13 | -0.14 |
| Average Basic Shares Outstanding | 165.40M | 164.54M | 163.75M | 163.36M | 163.21M |
| Average Diluted Shares Outstanding | 167.28M | 165.40M | 164.38M | 164.72M | 165.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |